Cloud DX Awarded $1.75 Million from NGen Supercluster to Create Advanced Medical Device Centre in Ontario

June 23, 2020

Cloud DX announced today it has been awarded $1.75 million in Supercluster funding from NGen, Canada’s Advanced Manufacturing Supercluster, to develop Pulsewave 2.0, a revolutionary solution to remotely monitor patients sent home from the hospital, including those vulnerable to or exposed to the novel coronavirus that causes COVID-19.

Cloud DX notes in countries experiencing peaks of coronavirus infection, hospitals have been overwhelmed with COVID+ patients who require vital sign monitoring. However, even before the pandemic struck, the Province of Ontario reported challenges in finding enough hospital rooms for patients during peak times. Part of the solution to this “hallway medicine” crisis lies in safely discharging as many patients as possible, as fast as possible, including COVID+ patients with non-acute symptoms who may require virtual care at home in order to fully recover from COVID-19.

The Cloud DX Connected Health platform gives doctors the automated monitoring ability they need to send many non-acute patients home sooner, freeing up beds, and relieving pressure on front line staff. Pulsewave 2.0 is the next iteration of Cloud DX’s award-winning blood pressure monitor.

This Bluetooth-enabled wrist cuff records and analyzes a patient’s radial artery pulse and delivers average breathing rate, average heart rate, and blood pressure measurements. The Connected Health platform consists of a mobile application for patients, clinician dashboards, smart software that automates the gathering of vital signs, patient symptom surveys, video, and text message capabilities, and customized healthcare content.

Cloud DX services allow doctors and nurses to set notification triggers that can alert them when a patient’s vital signs or symptoms change.  Connected Health and all of Cloud DX’s devices are Health Canada licensed and have been deployed by hospitals and clinics across the country.

NGen funding will help fast-track regulatory approval and transition to the manufacturing of the Pulsewave 2.0 and enable Cloud DX to begin manufacturing these innovative vital sign monitors at scale, in Canada. The company expects to create up to 10 new full-time jobs in Kitchener-Waterloo within the 12-month span of the project.

Once this state-of-the-art manufacturing center is fully operational, Cloud DX plans to expand its product line with additional ground-breaking devices currently under development, including the wearable Vitaliti™ continuous vital sign monitor which earned the company the Bold Epic Innovator Award as one of 3 winners of the Qualcomm Tricorder XPRIZE competition in 2017.

“Once production begins, Pulsewave 2.0 will be the only Health Canada licensed medical device that simultaneously gathers heart rate, respiration rate and blood pressure remotely from patients at home,” says Robert Kaul, CEO of Cloud DX. “Our solution is one key to helping Canadian healthcare providers monitor thousands of COVID-presumptive patients day after day, and to facilitating COVID-19 recovery by helping doctors quickly identify and focus on those patients whose condition has worsened.

“NGen is excited to support Cloud DX in the accelerated delivery of an effective and efficient solution for at-home oxygen and vitals monitoring and to get this solution in the hands of health care practitioners and their patients as soon as possible. This technology can play an instrumental role in relieving the burden on Canada’s health care systems while saving lives of patients recovering at home through continuous monitoring and quick intervention should conditions change,” says Jay Myers, CEO, NGen.

SourceCloud DX
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version